Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.
UCB has announced new three- and four-year data from Phase 3 open-label extension trials for bimekizumab (BIMZELX), showing sustained complete skin clearance in patients with moderate-to-severe plaque psoriasis. The findings were presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress.
Bimekizumab is the first approved medicine that selectively inhibits both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). The new data builds on previous evidence of the drug’s efficacy in providing long-term skin clearance and symptom relief.
“Achieving complete skin clearance is a key treatment target for all patients with plaque psoriasis, as it prevents the cumulative burden of disease and potentially progression to PsA,” says Richard B Warren, professor of dermatology at the University of Manchester and Northern Care Alliance NHS Foundation Trust, in a release. “It is therefore highly relevant to observe complete skin clearance sustained over four years in nearly half of patients who received bimekizumab, demonstrating long-term control of inflammation and the potential to improve patient outcomes.”
According to the results, among patients who achieved complete skin clearance (PASI 0) at Week 16 and entered the extension study (N=503), 48.9% maintained that clearance at every visit through year four. Furthermore, 72% sustained remission, defined in the abstract as PASI >0–≤2, over the same period. The study also found that 69.4% of these initial responders maintained a body surface area (BSA) of 1% or less at every visit to year four. The data also indicated a potential reduction in psoriatic arthritis (PsA) risk factors.
“The presentation of this new three- and four-year data is further evidence of the depth and durability of response achieved with bimekizumab treatment in psoriasis, even at highly stringent measures of disease control,” says Donatello Crocetta, head of medical and chief medical officer at UCB, in a release. “These results reinforce UCB’s commitment to developing evidence-driven solutions that aim to improve care for people living with chronic inflammatory diseases and reduce the risk of disease progression.”
